Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says

This article was originally published in The Pink Sheet Daily

Executive Summary

In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.

You may also be interested in...



FDA Mutual Reliance with EU on Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

FDA Mutual Reliance With EU On Inspections Is Slow Going

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

Updated: FDA Manufacturing Inspectors Could Be Further Divided Into Subspecialties

Industry could benefit from smoother plant inspections.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS078143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel